ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer


Key opinion leaders discuss various trial data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding the management of metastatic HER2-positive breast cancer.

Data from the following clinical trials is discussed:

  • Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).(Lin, ASCO 2020 Abstract 1005)

  • The recent FDA approvals for relapsed refractory HER2+ MBC:
    • Trastuzumab deruxtecan in Previously Treated HER2+ Breast Cancer: DESTINY-BREAST01 (Modi, NEJM 2020)

    • Fam-trastuzumab deruxtecan-nxki

    • Tucatinib

    • Neratinib

  • The potential role of trastuzumab deruxtecan in HER2-low expressing tumors: phase 3, DESTINY-Breast04; NCT03734029

Related Videos
Judy C. Boughey, MD
Francisco J. Esteva, MD, PhD
Stephanie L. Graff, MD
Related Content